Other Assets - Additional Information (Detail)	3 Months Ended	6 Months Ended		3 Months Ended			12 Months Ended			12 Months Ended		3 Months Ended			6 Months Ended
	Mar. 31, 2013 USD ($)	Mar. 31, 2013 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 OctoPlus N.V. EUR (€)	Dec. 31, 2012 Investment In Vessix Vascular, Inc. USD ($)	Mar. 31, 2010 Investment In Vessix Vascular, Inc. USD ($)	Sep. 30, 2010 Investment In Vessix Vascular, Inc. USD ($)	Aug. 31, 2009 Investment In Vessix Vascular, Inc. USD ($)	Sep. 30, 2012 OctoPlus N.V. USD ($)	Dec. 31, 2010 Nexeon MedSystems, Inc. USD ($)	Mar. 31, 2013 Nexeon MedSystems, Inc. USD ($)	Mar. 31, 2013 ViaCyte, Inc. USD ($)	Mar. 31, 2013 Maximum USD ($)	Mar. 31, 2012 Maximum USD ($)	Mar. 31, 2013 Maximum USD ($)	Mar. 31, 2012 Maximum USD ($)	Dec. 31, 2012 Maximum Investment In Vessix Vascular, Inc. USD ($)	Mar. 31, 2013 Maximum Nexeon MedSystems, Inc.	Mar. 31, 2013 Maximum CeloNova BioSciences, Inc.	Mar. 31, 2013 Maximum ViaCyte, Inc.
Other Assets [Line Items]
Investment cost, cost method									$ 900,000		$ 6,500,000	$ 5,200,000
Offer price to purchase all issued and outstanding ordinary shares				€ 0.52
Gain on sale of investments	100,000
Impairment loss on other assets										4,100,000		4,700,000
Company's ownership percentage																		20.00%	5.00%	5.00%
Additional impairment loss other than temporary												100,000
Cost method of investment												400,000
Investment in Vessix								2,000,000
Follow-on investment						500,000
Impairment loss on investment							2,400,000
Gain on sale of investment		1,458,000	170,000		1,200,000
Potential proceeds on achievement of future milestones																	4,200,000
Revenue recognized from activity with companies in which it had strategic investment													$ 100,000	$ 100,000	$ 100,000	$ 100,000